Improving the efficacy of trastuzumab in breast cancer

Cancer Science

Volumn 98, Issue 6, 2007, Pages 767-771

  Suzuki, Eiji ^a   Toi, Masakazu ^b  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FC RECEPTOR; FLUOROURACIL; FUCOSE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; INHIBITION KINETICS; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 34247862352     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00455.x     Document Type: Review

References (57)

1. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
2. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
3. Baselga J, Norton L, Masui L et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
4. Baselga J, Norton L, Albanell J et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
5. Pegram M, Hsu S, Lewis G et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
6. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-51.
7. Pegram M, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 19: 739-49.
8. Braakhuis BJ, Hill BT, Dietel M et al. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 1994; 14: 205-8.
9. Riou JF, Petigenet O, Combeau C et al. Cellular uptake and efflux of docetaxel and paclitaxel in P388 cell line. Proc Am Assoc Cancer Res 1994; 35: 385.
10. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55.
11. Fromes Y, Gounon P, Veitia R et al. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 1996; 15: 377-88.
12. O'Donovan N, Beryt M, Duffy MJ et al. HER-2/neu and apoptosis in breast cancer. Proc Am Assoc Cancer Res 2002; 43: 603.
13. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-33.
14. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004; 22: 1071-7.
15. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-69.
16. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-95.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
18. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
19. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG study. Breast Cancer Res Treat 2005: 94 (Suppl 1): S5a.
20. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.
21. Bines J, Murad A, Lago S et al. Primary treatment with weekly docetaxel (Taxotere) and trastuzumab (Herceptin) for HER-2 overexpressing locally advanced breast cancer. Eur J Cancer 2003; 1 (Suppl 5): S114.
22. Burstein HJ, Harris LN, Gelman R et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study. J Clin Oncol 2003; 21: 46-53.
23. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
24. Coudert BP, Arnould L, Moreau L, et al. Pathological complete response rate with neoadjuvant trastuzumab and decetaxel chemotherapy in HER-2 positive (3+) locally advanced breast cancer (Abstract no. 128P). Ann Oncol 2004; 15 (Suppl 3): 34.
25. Harris LN, Burstein H, Gelman R et al. Preoperative trastuzumab and vinorelbine is a well-tolerated, active regimen for Her2, 3+/FISH+ stage II/III breast cancer (Abstract no. 397). Eur J Cancer 2003; 1 (Suppl 5): S121.
26. Hurley J, Dolny P, Silva O et al. Neoadjuvant herceptin/taxotere/ cisplatin in the treatment of locally advanced and inflammatory breast cancer (Abstract no. 196). 38th Annual Meeting of the American Society of Clinical Oncology, 18-21 May 2002, Orlando, FL, USA.
27. Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 2003; 4: 348-53.
28. Kelly H, Kimmick G, Dees EC et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006; 7: 237-43.
29. Ahluwalia MS, Daw HA. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer. J Clin Oncol 2005; 20: 7759-60.
30. Hurwitz E, Stancovski I, Sela M et al. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995; 92: 3353-7.
31. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
32. Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 2001; 84: 4744-9.
33. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-51.
34. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134: 445-50.
35. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.
36. Koene HR, Kleijer M, Algra J, von Roos D, dem Born AE, de Haas M. FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-14.
37. Wu J, Edberg JC, Redecha PB et al. A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-70.
38. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5.
39. Arnould L, Gelly M, Penault-Liorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67.
40. Izumi Y, Xu L, di Tomaso E et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
41. Nahta R, Takahashi T, Ueno NT et al. P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64: 2343-6.
42. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27.
43. Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-7.
44. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-9.
45. Storniolo A, Burris H, Pegram M et al. A phase I, open label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen (Abstract no. 559). J Clin Oncol 2005; 23 (Suppl 16): S18.
46. Blackwell KL, Kaplan EH, Franco SX et al. A phase II, open label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22 (Suppl 14): 3006.
47. Burstein H, Storniolo AM, Franco S et al. A phase II, open label, multicenter study of GW572016 in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 2004; 15 (Suppl 13): A103.
48. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-37.
49. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343-6.
50. Walshe JM, Denduluri N, Berman AW et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006; 6: 535-9.
51. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2: 296-313.
52. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10 314-19.
53. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73.
54. Niwa R, Shoji-Hosaka E, Sakurada M et al. Defucosylated anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33.
55. Okazaki A, Shoji-Hosaka E, Nakamura K et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgRIIIa. J Mol Biol 2004; 336: 1239-49.
56. Niwa R, Hatanaka S, Shoji-Hosaka E et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgRIIIa functional polymorphism. Clin Cancer Res 2004; 10: 6248-55.
57. Suzuki E, Niwa R, Sagi S et al. A non-fucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity of breast cancer patients. Clin Cancer Res 2007; 13: 1875-82.